Hong Kong will remain as an attractive destination for foreign pharmaceutical firms due to rising medical demands from the ageing population. In addition, its proximity from China will also allow companies to expand into the world's largest emerging market.
Headline Expenditure Projections
* Pharmaceuticals : HKD11.24bn (USD1.45bn) in 2013 to HKD12.12bn (USD1.56bn) in 2014; +7.8% in local currency terms and US dollar terms. Forecast broadly in line with Q314 .
* Healthcare: HKD122.00bn (USD15.73bn) in 2013 to HKD130.97bn (USD16.85bn) in 2014; +7.3% in local currency terms and US dollar terms. Forecast broadly in line with Q314 .
Full Report Details at
- http://www.fastmr.com/prod/861834_hong_kong_pharmaceuticals_healthcare_report_q4.aspx?afid=101
Risk/Reward Ratings
Hong Kong's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 64.6 out of 100 in our newly improved RRR system. The country scores above average for most indicators and sub-indicators, including per capita pharmaceutical expenditure, sector value growth and pensionable population. Consequently with this high score, Hong Kong is ranked fifth, above China, out of the 19 key Asia Pacific markets.
Key Trends And Developments
* In July 2014, Luye Pharma raised USD764mn following its initial public offering on the Hong Kong Stock Exchange. The firm was previously listed in New York and Singapore.
* In June 2014, Italy-based Abiogen Pharma and Hong Kong- based Lee's Pharmaceutical Holdings signed a licensing, distribution and supply deal. Under the terms of the transaction, Abiogen Pharma will market neridronic acid (6-amino-1-idroxyesilidene-1, 1-bisphosphonate) in mainland China, Taiwan, Macau and Hong Kong. The partnership will help China and Taiwan patients to fight critical rare diseases for which there are no other treatment options available.
* In May 2014, Taiwan-based active pharmaceutical ingredient firm, ScinoPharm Taiwan, and Lee's Pharmaceutical Holdings announced two collaboration agreements for China. The two parties will jointly develop and produce fondaparinux, and travoprost...
The Hong Kong Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Hong Kong Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hong Kong pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Hong Kong to test other views - a key input for successful budgeting and strategic business planning in the Hong Kong pharmaceutical and healthcare market.
* Target business opportunities and risks in the Hong Kong pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hong Kong.
* Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
read full article